NASDAQ: OSUR
Orasure Technologies Inc Stock

$4.35+0.03 (+0.69%)
Updated Jul 2, 2026
OSUR Price
$4.35
Fair Value Price
$1.80
Market Cap
$299.49M
52 Week Low
$2.08
52 Week High
$4.58
P/E
-4.18x
P/B
0.96x
P/S
1.85x
PEG
N/A
Dividend Yield
N/A
Revenue
$113.02M
Earnings
-$75.07M
Gross Margin
42.2%
Operating Margin
-64.81%
Profit Margin
-66.4%
Debt to Equity
0.21
Operating Cash Flow
-$43M
Beta
1.06
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A

OSUR Overview

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine OSUR's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
B
OSUR
Ranked
#40 of 41

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$10.16A
$24.84A
$17.16B
View Top Medical Stocks

Be the first to know about important OSUR news, forecast changes, insider trades & much more!

OSUR News

Overview

Due Diligence Score

Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OSUR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OSUR ($4.35) is overvalued by 141.77% relative to our estimate of its Fair Value price of $1.80 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
OSUR ($4.35) is not significantly undervalued (141.77%) relative to our estimate of its Fair Value price of $1.80 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
OSUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OSUR due diligence checks available for Premium users.

Valuation

OSUR fair value

Fair Value of OSUR stock based on Discounted Cash Flow (DCF)

Price
$4.35
Fair Value
$1.80
Overvalued by
141.77%
OSUR ($4.35) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OSUR ($4.35) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OSUR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

OSUR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-4.18x
Industry
45.19x
Market
8.54x

OSUR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.96x
Industry
3.43x
OSUR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

OSUR's financial health

Profit margin

Revenue
$27.9M
Net Income
-$22.4M
Profit Margin
-80.1%
OSUR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OSUR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$379.2M
Liabilities
$65.8M
Debt to equity
0.21
OSUR's short-term assets ($240.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OSUR's short-term assets ($240.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OSUR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OSUR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.9M
Investing
-$913.0k
Financing
-$6.3M
OSUR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OSUR vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
OSURD$299.49M+0.69%-4.18x0.96x
UTMDC$231.73M+3.04%21.53x1.93x
SMTIA$227.63M+2.35%-6.40x32.39x
KRMDB$206.24M+2.05%-89.80x12.19x
INFUA$205.05M+1.40%26.74x3.49x

Orasure Technologies Stock FAQ

What is Orasure Technologies's quote symbol?

(NASDAQ: OSUR) Orasure Technologies trades on the NASDAQ under the ticker symbol OSUR. Orasure Technologies stock quotes can also be displayed as NASDAQ: OSUR.

If you're new to stock investing, here's how to buy Orasure Technologies stock.

What is the 52 week high and low for Orasure Technologies (NASDAQ: OSUR)?

(NASDAQ: OSUR) Orasure Technologies's 52-week high was $4.58, and its 52-week low was $2.08. It is currently -5.02% from its 52-week high and 109.13% from its 52-week low.

How much is Orasure Technologies stock worth today?

(NASDAQ: OSUR) Orasure Technologies currently has 68,848,553 outstanding shares. With Orasure Technologies stock trading at $4.35 per share, the total value of Orasure Technologies stock (market capitalization) is $299.49M.

Orasure Technologies stock was originally listed at a price of $5.00 in Dec 31, 1997. If you had invested in Orasure Technologies stock at $5.00, your return over the last 28 years would have been -13%, for an annualized return of -0.5% (not including any dividends or dividend reinvestments).

How much is Orasure Technologies's stock price per share?

(NASDAQ: OSUR) Orasure Technologies stock price per share is $4.35 today (as of Jul 2, 2026).

What is Orasure Technologies's Market Cap?

(NASDAQ: OSUR) Orasure Technologies's market cap is $299.49M, as of Jul 5, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Orasure Technologies's market cap is calculated by multiplying OSUR's current stock price of $4.35 by OSUR's total outstanding shares of 68,848,553.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.